Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

BACKGROUND: Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symptoms and health status, measured by the Functional Assessment of Cancer Ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cella, D, Escudier, B, Rini, B, Chen, C, Bhattacharyya, H, Tarazi, J, Rosbrook, B, Kim, S, Motzer, R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3668468/
https://ncbi.nlm.nih.gov/pubmed/23579211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.145
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados